Immune Response BioPharma, Inc. today announced that it plans to offer $100 million aggregate principal amount of 7% Senior Notes due 2020 in a proposed private offering to “Accredited Investors” and “qualified institutional buyers,” as defined in Rule 144A under the Securities Act of 1933, as amended, and non-U.S. persons outside the United States under Regulation S under the Securities Act of 1933. The 2020 notes offer expires 08/02/2012.
The gross proceeds from the offering of the notes will be deposited into an escrow account at Capital One Bank and used for working capital and to advance the clinical pipeline, build a manufacturing plant in Virginia for REMUNE an HIV/AIDS Vaccine and to file an NDA New Drug Application for REMUNE, and begin Phase 2 Dose Ranging Trial for NeuroVax MS vaccine.
The notes will not be registered under the Securities Act of 1933 or any state securities laws and, unless so registered, may not be offered or sold except pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933 and applicable state securities laws
A circular and prospectus of the private offering of $100 million aggregate principal 7% Senior Notes due 2020 bonds is available from Immune Response BioPharma, Inc. at info@immuneresponsebiopharma.com
www.immuneresponsebiopharma.com
Forward-Looking Statement
Some of the statements made in this press release are forward looking in nature. These statements are based on management’s current expectations or beliefs. These forward looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside Immune Response BioPharma, Inc.’s control, which could cause actual events to differ materially from those expressed or implied by the statements. The most important factors that could prevent Immune Response BioPharma, Inc. from achieving its stated goals include, but are not limited to: the current uncertainty in the global financial markets and the global economy. Including but not limited to the uncertainties regarding the approval of biopharmaceutical products in a highly regulated market.
